Table 4.
Potential association between clinical and baseline characteristics and the risk of developing SBa
| Odds ratiob (95% CI) | P‐valuec | |
|---|---|---|
| Baseline clinical and patient characteristics | ||
| Pretreatment HR (<70 bpm vs. ≥70 bpm) | 4.929 (2.946–8.245) | < 0.0001 |
| Age (≥65 years vs. <65 years) | 1.434 (0.997–2.064) | 0.0521 |
| Gender (male vs. female) | 1.154 (0.882–1.510) | 0.2973 |
| Smoking status (current/former vs. never smoker) | 1.001 (0.757–1.323) | 0.9954 |
| Race (Asian vs. non‐Asian) | 0.879 (0.671–1.151) | 0.3488 |
| ECOG PS (≥2 vs. 0/1) | 0.686 (0.471–0.998) | 0.0485 |
| Concomitant medications | ||
| Beta‐blocker use (yes vs. no) | 1.390 (0.916–2.110) | 0.1221 |
| Nondihydropyridine CCB use (yes vs. no) | 1.465 (0.470–4.569) | 0.5109 |
| Metoclopramide use (yes vs. no) | 1.203 (0.894–1.618) | 0.2232 |
| General antihypertensive used (yes vs. no) | 0.836 (0.629–1.111) | 0.2174 |
bpm, beats per minute; CCB, calcium channel blocker; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, heart rate; SB, sinus bradycardia.
a
SB is defined as any HR <60 bpm while receiving crizotinib treatment.
b
Odds ratio >1 indicates higher odds of developing SB in the first category, and odds ratio <1 indicates higher odds in the second category.
c
Wald χ 2 test.
d
Excluding beta‐blockers and nondihydropyridine CCBs.